Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.33 |
| ▸ | FEN1 | P39748 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6807269 | 1.00 | DRD2 (0.41) | DRD2DRD4DRD3POLBSMN1; SMN2 | |
| SCHEMBL6811661 | 0.86 | SLC6A7 (0.42) | DRD2DRD4DRD3SMN1; SMN2KDM4E | |
| SCHEMBL6811657 | 0.86 | SLC6A7 (0.42) | DRD2DRD4DRD3SMN1; SMN2KDM4E | |
| SCHEMBL6811666 | 0.86 | SLC6A7 (0.42) | DRD2DRD4DRD3SMN1; SMN2KDM4E | |
| SCHEMBL6645590 | 0.84 | DRD2 (0.44) | DRD2DRD4DRD3POLBSMN1; SMN2 | |
| SCHEMBL6806995 | 0.81 | LMNA (0.41) | SMN1; SMN2KDM4EALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL6808189 | 0.81 | LMNA (0.41) | SMN1; SMN2KDM4EALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL6806991 | 0.81 | LMNA (0.41) | SMN1; SMN2KDM4EALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL6803436 | 0.80 | SLC6A7 (0.40) | DRD2DRD4DRD3SMN1; SMN2KDM4E | |
| SCHEMBL6803438 | 0.80 | SLC6A7 (0.40) | DRD2DRD4DRD3SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180901-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | ASTRAZENECA AB (SE) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180901-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | MMP13, MMP3, MMP2 | DRD2 2168/4885DRD4 2928/4885DRD3 2441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.